You are here: Industry Insights > Eiger

News List

Eiger Announces Positive Results of COVID-19 Trial americanpharmaceuticalreview
October 22, 2020
Eiger BioPharmaceuticals announced results of the ILIAD Study (Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19), an investigator sponsored randomized trial of Peginterferon Lambda (Lambda) in outpatients with ...
Eiger Announces Results of Study in Patients with Mild, Uncomplicated COVID-19 americanpharmaceuticalreview
October 09, 2020
Eiger BioPharmaceuticals announced results of an investigator sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.
Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19 prnewswire
September 30, 2020
Eiger BioPharmaceuticals, Inc. announced results of an investigator sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.
Eiger Receives FDA Breakthrough Therapy Designation for Treatment of Hepatitis Delta Virus Infection americanpharmaceuticalreview
August 22, 2019
Eiger BioPharmaceuticals has announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for peginterferon lambda (Lambda) for the treatment of hepatitis delta virus (HDV) infection.
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib americanpharmaceuticalreview
December 19, 2018
Eiger BioPharmaceuticals announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lonafarnib for the treatment of hepatitis delta virus (HDV) infection......
Eiger Announces FDA Acceptance of IND Application for Lonafarnib americanpharmaceuticalreview
December 05, 2018
Eiger BioPharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for lonafarnib....
Eiger Announces Positive Meeting with FDA on Progeria Program americanpharmaceuticalreview
September 05, 2018
Eiger BioPharmaceuticals has received minutes from a pre-investigational new drug (pre-IND) meeting with the Division of Gastroenterology and Inborn Errors Products of the U.S. Food and Drug Administration (FDA) for lonafarnib in the treatment of Hutchins
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results biospace
March 13, 2018
Eiger BioPharmaceuticals, Inc.today financial results for the three months and year ended December 31, 2017 and provided a business update.